Nevertheless, Christa Müller does not think it makes sense to simply administer ceritinib as a CD39 inhibitor in certain cancers. These are extremely difficult to treat - they usually hardly respond to therapies." "We were able to show this not only in the test tube, but also in cultures with so-called triple-negative breast cancer cells. With success: "One of the substances, ceritinib, also blocks the conversion of ATP by CD39," Schäkel is pleased to report. We now looked at whether they also work against CD39."Īt the start of the study, there were a total of 50 different agents approved for certain diseases that inhibit protein kinases. The nice thing is that there are already approved drugs that inhibit protein kinases. "These include, for example, the so-called protein kinases. Müller carried out many of the central experiments in the study. The Bonn research group therefore pursued a new search strategy in the study: "There are other enzymes in the body than CD39 that also process ATP," explains Laura Schäkel. So far, the search has been largely unsuccessful.
"So the body's own defenses would not be suppressed on the contrary, they would be turned on extra sharp."ĥ0 approved active substances scrutinized "Instead, ATP would accumulate around the cancer cells, which would actually stimulate the immune response," says Müller. Because without adenosine, tumors would no longer be protected from the immune system. "If CD39 is inhibited, hardly any adenosine is produced."Īround the globe, pharmaceutical researchers are therefore searching for an active ingredient that slows down CD39. Christa Müller from the Institute of Pharmacy at the University of Bonn. "It catalyzes the first of the conversion steps," explains Prof. They carry various enzymes on their surface that then convert the ATP to adenosine in several steps. It also ensures that the malignant cells migrate to other organs and form metastases there.Īdenosine is produced from adenosine triphosphate, or ATP for short. At the same time, it stimulates the formation of new blood vessels that supply the tumor with oxygen and nutrients. On the one hand, the molecule suppresses the immune system. Many cancer cells surround themselves with a dense cloud of adenosine. In the medium term, this could pave the way for new anti-cancer drugs. The researchers now want to further optimize the compound. This is shown in a study by the University of Bonn and the University Medical Center Hamburg-Eppendorf, which has now appeared in the Journal for ImmunoTherapy of Cancer. But a drug already approved for other purposes can apparently render this weapon harmless. Many tumor cells mist themselves with a protective perfume that disables the immune system. Johannes Seiler Dezernat 8 - Hochschulkommunikation Rheinische Friedrich-Wilhelms-Universität Bonn Saving Earth Britannica Presents Earth’s To-Do List for the 21st Century.Therapeutic drug renders cancer cell weapon harmless.Britannica Beyond We’ve created a new place where questions are at the center of learning.100 Women Britannica celebrates the centennial of the Nineteenth Amendment, highlighting suffragists and history-making politicians.
#Atp production how to#
0 kommentar(er)
